Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...
An agentic AI-based approach to end-to-end bug resolution using both error logs and waveforms.
Findings from the phase 1/2 BRUIN study (NCT03740529) show that pirtobrutinib (Jaypirca), a Bruton tyrosine kinase inhibitor (BTKi), monotherapy offers promising clinical efficacy and a favorable ...
Key Takeaways. TTP following R-CHOP is a strong prognostic factor for survival in R/R DLBCL, with shorter TTP linked to ...
Scientific studies claim that modern music has become simpler than ever before, both lyrically and musically. But are they ...
New U.S. wildlife chief Brian Nesvik told Cowboy State Daily on Thursday that It could take another two years to work through ...
An analysis of Tesla’s patent applications shows a slower pace of innovation in the last 2 years and a shift toward AI ...
The waveLINE-003 trial demonstrates the efficacy of zilovertamab vedotin combined with standard therapy, with manageable safety profiles in difficult-to-treat DLBCL patients. ADCs provide logistical ...
Researchers have shown that glioblastoma can take over the skull marrow to dissolve bone and feed its own growth, suggesting ...
Association of paleopalynological data from the Nanxiong Basin, south China, and late Paleocene niche expansion in endemic Asian fossil mammals.
Objective To determine whether a full-scale randomised control trial (RCT) assessing the efficacy and cost-effectiveness of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback